Cart
sales@molnova.com
MitoBloCK-6
CAS No. 303215-67-0
MitoBloCK-6( —— )
Catalog No. M35338 CAS No. 303215-67-0
MitoBloCK-6 is a potent Erv1/ALR inhibitor with IC50 values of 900 nM and 700 nM, respectively, and also inhibits Erv2 with an IC50 of 1.4 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 31 | In Stock |
|
| 10MG | 45 | In Stock |
|
| 25MG | 72 | In Stock |
|
| 50MG | 117 | In Stock |
|
| 100MG | 183 | In Stock |
|
| 200MG | 276 | In Stock |
|
| 500MG | 480 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMitoBloCK-6
-
NoteResearch use only, not for human use.
-
Brief DescriptionMitoBloCK-6 is a potent Erv1/ALR inhibitor with IC50 values of 900 nM and 700 nM, respectively, and also inhibits Erv2 with an IC50 of 1.4 μM.
-
DescriptionMitoBloCK-6 is a potent Erv1/ALR inhibitor, with an IC50 of 900 nM and 700 nM, respectively. MitoBloCK-6 also inhibits Erv2 (IC50=1.4 μM). MitoBloCK-6 can induce apoptosis via cytochrome c release in hESCs.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number303215-67-0
-
Formula Weight357.23
-
Molecular FormulaC19H14Cl2N2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (139.97 mM)
-
SMILESOc1c(Cl)cc(Cl)cc1\C=N\c1ccc(Nc2ccccc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dabir DV, et, al. A small molecule inhibitor of redox-regulated protein translocation into mitochondria. Dev Cell. 2013 Apr 15;25(1):81-92. ?
molnova catalog
related products
-
CMLD-2
CMLD-2 is an inhibitor of HuR-ARE interaction (Ki: 350 nM) that competitively binds HuR protein and disrupts its interaction with adenine element-rich (ARE) mRNA targets.
-
Dihydrolycorine
Dihydrolycorine-HCL(DL) shows hypotensive effects, it can block alpha 1-adrenoceptors.
-
Exisulind
Exisulind induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer.
